Cetrorelix vs Triptorelin

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context In IVF, cetrorelix is used under two standard protocols. The multiple-dose protocol administers 0.25mg subcutaneously once daily starting from stimulation day 5 or 6, continuing until the day of oocyte trigger — this prevents LH surge during the follicular growth phase. The single-dose protocol administers 3mg once when the leading follicle reaches approximately 14mm, providing LH suppression for approximately 96 hours; a supplemental 0.25mg dose is added if trigger has not occurred by day 4. Both protocols have established efficacy data and are used depending on clinic preference and patient response characteristics. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.

Potent GnRH agonist; single pulse stimulates LH/FSH surge and restores HPG axis after suppression (e.g., post-steroid cycle)

Triptorelin is a synthetic decapeptide GnRH agonist with a longer half-life than endogenous GnRH, used clinically to produce controlled hormonal suppression of the reproductive axis via receptor downregulation. Unlike the brief stimulatory effect of native GnRH, continuous or depot administration of triptorelin paradoxically desensitizes pituitary GnRH receptors, producing sustained suppression of LH, FSH, and sex hormone levels through a process known as medical castration. Clinical trials have established triptorelin efficacy for androgen deprivation therapy in prostate cancer, treatment of central precocious puberty, and hormonal management of endometriosis and uterine fibroids. Triptorelin is an FDA-approved prescription medication (Trelstar) available in depot formulations; it requires specialist-supervised monitoring due to an initial hormonal flare on commencement and the significant physiological effects of prolonged sex hormone suppression. Triptorelin for HPTA restart (PCT context) Outside its approved indications, triptorelin has been discussed in post-cycle therapy (PCT) and testosterone replacement therapy (TRT) restart contexts. The rationale is mechanistic: a single low dose of triptorelin triggers a brief, intense LH and FSH pulse before inducing pituitary downregulation — this initial agonist surge may be sufficient to re-sensitise a suppressed hypothalamic-pituitary-gonadal (HPG) axis following prolonged androgen administration that has blunted endogenous LH/FSH production. Some research and anecdotal literature describes single-dose triptorelin protocols (typically 100–200mcg administered once) as an HPTA restart approach, with the goal of re-initiating endogenous testosterone production. This use is not FDA-approved, not evaluated in randomised controlled trials for this indication, and not a standard of care in any guideline. It represents an off-label research and community-practice area. Triptorelin's mechanism — producing sustained hormonal suppression — means that incorrect dosing or repeated administration would achieve the opposite of the desired restart effect; this context requires qualified clinical supervision. PeptideBase does not endorse off-label use; this is informational context about how the compound is discussed in research and clinical community settings.